CYP17A1 Antibody [G22K11]

Catalog No.: F6128

Application: Reactivity: Human, Mouse, Rat

Lane 1: Mouse testis, Lane 2: Rat testis

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:50 IF1:200

Application
WB, IP, IF

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Mouse, Rat

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
55 kDa

Datasheet & SDS

生物学的記述

Specificity
CYP17A1 Antibody [G22K11] detects endogenous levels of total CYP17A1 protein.

Clone
G22K11

Synonym(s)
Steroid 17-alpha-hydroxylase/17,20 lyase; 17-alpha-hydroxyprogesterone aldolase; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17 (Cytochrome P450c17); Steroid 17-alpha-monooxygenase; CYP17A1; CYP17; S17AH

Background
CYP17A1 (cytochrome P450 17A1, also known as CYP17 or P450c17) is a bifunctional steroidogenic cytochrome‑P450 enzyme expressed predominantly in the adrenal cortex and gonads, where it catalyzes both 17α‑hydroxylase and 17,20‑lyase reactions on C21 steroids such as pregnenolone and progesterone to generate key androgen precursors. In the adrenal zona reticularis and gonadal Leydig and theca cells, CYP17A1 first converts pregnenolone to 17α‑hydroxypregnenolone and then cleaves the C17–C20 bond to yield dehydroepiandrosterone (DHEA), the first committed step in the classical androgen‑synthesis pathway that leads to testosterone and downstream dihydrotestosterone. CYP17A1 also participates in the backdoor and C11‑oxy androgen‑production pathways by acting on 11‑oxygenated precursors, thereby providing alternative routes to potent androgenic steroids in pathological and developmental contexts. The enzyme is embedded in the mitochondrial membrane with its heme‑containing active site oriented toward the matrix, and its activity is tightly regulated by substrate availability, electron‑donor systems, and transcriptional control of steroid‑pathway genes. In castration‑resistant prostate cancer, CYP17A1 remains a major source of intratumoral and adrenal androgen production, and it is the primary target of abiraterone, which is converted in vivo to Δ4‑abiraterone (D4A); D4A inhibits CYP17A1 as well as other steroidogenic enzymes such as 3β‑hydroxysteroid dehydrogenase and 5α‑reductase and further antagonizes the androgen receptor, thereby suppressing synthesis and action of 5α‑dihydrotestosterone and blocking androgen‑driven growth of tumor cells.

Background

CYP17A1 (cytochrome P450 17A1, also known as CYP17 or P450c17) is a bifunctional steroidogenic cytochrome‑P450 enzyme expressed predominantly in the adrenal cortex and gonads, where it catalyzes both 17α‑hydroxylase and 17,20‑lyase reactions on C21 steroids such as pregnenolone and progesterone to generate key androgen precursors. In the adrenal zona reticularis and gonadal Leydig and theca cells, CYP17A1 first converts pregnenolone to 17α‑hydroxypregnenolone and then cleaves the C17–C20 bond to yield dehydroepiandrosterone (DHEA), the first committed step in the classical androgen‑synthesis pathway that leads to testosterone and downstream dihydrotestosterone. CYP17A1 also participates in the backdoor and C11‑oxy androgen‑production pathways by acting on 11‑oxygenated precursors, thereby providing alternative routes to potent androgenic steroids in pathological and developmental contexts. The enzyme is embedded in the mitochondrial membrane with its heme‑containing active site oriented toward the matrix, and its activity is tightly regulated by substrate availability, electron‑donor systems, and transcriptional control of steroid‑pathway genes. In castration‑resistant prostate cancer, CYP17A1 remains a major source of intratumoral and adrenal androgen production, and it is the primary target of abiraterone, which is converted in vivo to Δ4‑abiraterone (D4A); D4A inhibits CYP17A1 as well as other steroidogenic enzymes such as 3β‑hydroxysteroid dehydrogenase and 5α‑reductase and further antagonizes the androgen receptor, thereby suppressing synthesis and action of 5α‑dihydrotestosterone and blocking androgen‑driven growth of tumor cells.

References
[1] Mak PJ, et al. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15856-61. [2] van Rooyen D, et al. J Steroid Biochem Mol Biol. 2020 May;199:105614.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%